Ctexli
Named-patient access overview. Ctexli is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Ctexli (chenodiol, also known as chenodeoxycholic acid) is an oral bile acid replacement therapy developed by Mirum Pharmaceuticals. The US Food and Drug Administration approved Ctexli in February 2024 for the treatment of cerebrotendinous xanthomatosis (CTX) in adults, a rare autosomal recessive lipid storage disorder caused by mutations in the CYP27A1 gene. Ctexli supplements deficient endogenous chenodeoxycholic acid, suppresses the abnormal accumulation of cholestanol and bile alcohols, and is given as a 250 mg oral tablet three times daily with food. Treatment is supervised by a metabolic specialist or neurologist familiar with inherited bile acid synthesis disorders.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Ctexli
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Ctexli is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Ctexli in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Ctexli
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.